Rgenta Therapeutics, Inc. filed a Form D with the SEC, reporting $41.9M sold, of a $130.1M offering.

{
  "signal_id": "fd-0001231919-26-001529",
  "signal_type": "sec-form-d-funding",
  "signal_subtype": "newFilingCompany",
  "detected_at": "2026-11-03T00:00:00+00:00",
  "company": {
    "name": "Rgenta Therapeutics, Inc.",
    "domain": "rgentatx.com"
  },
  "data": {
    "cik": "0001801266",
    "phone": "781-608-3996",
    "detail": "The filing suggests a venture-backed biotech with active discovery and clinical-stage execution, likely spending across research, translational biology, and trial-related infrastructure. Vendors should pay attention to demand for CROs, lab and assay services, data/AI tools, regulatory support, and specialized manufacturing or CMC partners.",
    "topics": [
      "Biotech",
      "RNA Therapeutics",
      "Oncology",
      "CNS Disorders",
      "Clinical Development"
    ],
    "summary": "Rgenta Therapeutics develops RNA-targeting oral small molecules for oncology and CNS diseases. This Form D reports a cash raise with $41.9M sold out of a $130.1M offering, which signals meaningful capital available for a biotech focused on platform R&D and clinical progress.",
    "website": "https://rgentatx.com",
    "location": "Woburn, MASSACHUSETTS",
    "file_date": "2026-11-03",
    "form_type": "D",
    "relevance": 0.8,
    "confidence": "high",
    "exemptions": [
      "06b"
    ],
    "filing_url": "https://www.sec.gov/Archives/edgar/data/1801266/000123191926001529/",
    "source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001801266&type=D&dateb=&owner=include&count=40",
    "entity_name": "Rgenta Therapeutics, Inc.",
    "entity_type": "Corporation",
    "jurisdiction": "DELAWARE",
    "primary_topic": "Biotech Fundraise",
    "revenue_range": "Decline to Disclose",
    "business_state": "MA",
    "industry_group": "Other Technology",
    "related_persons": [
      {
        "name": "Hualin Xi",
        "roles": [
          "Executive Officer",
          "Director"
        ]
      },
      {
        "name": "Yichao Fan",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Debasish Roychowdhury",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Julia Kaufman",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Sean Zhang",
        "roles": [
          "Director",
          "Promoter"
        ]
      },
      {
        "name": "Cillian King",
        "roles": [
          "Director",
          "Promoter"
        ]
      },
      {
        "name": "James Kasuboski",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Travis Wager",
        "roles": [
          "Executive Officer"
        ]
      }
    ],
    "total_investors": 9,
    "total_remaining": 88254972,
    "accession_number": "0001231919-26-001529",
    "securities_types": [
      "Equity",
      "Debt"
    ],
    "business_location": "Brookline, MA",
    "total_amount_sold": 41852307,
    "resolved_entity_name": "Rgenta Therapeutics, Inc.",
    "resolved_entity_type": "operating_company",
    "total_offering_amount": 130107279,
    "company_domain_confidence": 10,
    "has_non_accredited_investors": false
  }
}

curl https://signals.autobound.ai/v1/signals/fd-0001231919-26-001529 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"rgentatx.com","limit":20}'